Policy | July 02, 2025
India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
This strategic expansion marks a significant step in the company's global growth strategy
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Subscribe To Our Newsletter & Stay Updated
